• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Anti-influenza Drug Discovery: Identification of an Orally Bioavailable Quinoline Derivative through Activity- and Property-Guided Lead Optimization

tetano

Editor, Senior Moderator
ChemMedChem. 2012 Jul 23. doi: 10.1002/cmdc.201200259. [Epub ahead of print]
Anti-influenza Drug Discovery: Identification of an Orally Bioavailable Quinoline Derivative through Activity- and Property-Guided Lead Optimization.
Yeh JY, Coumar MS, Shiao HY, Lin TJ, Lee YC, Hung HC, Ko S, Kuo FM, Fang MY, Huang YL, Hsu JT, Yeh TK, Shih SR, Chao YS, Horng JT, Hsieh HP.
Source

Institute of Biotechnology and Pharmaceutical Research, National Health Research Institutes, 35 Keyan Rd, Zhunan, Miaoli County 350 (Taiwan, RoC).
Abstract

From a high-throughput screening (HTS) hit with inhibitory activity against virus-induced cytophathic in the low micromolar range, we have developed a potent anti-influenza lead through careful optimization without compromising the drug-like properties of the compound. An orally bioavailable compound was identified as a lead agent with nanomolar activity against influenza, representing a 140-fold improvement over the initial hit.

Copyright ? 2012 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.

PMID:
22821876
[PubMed - as supplied by publisher]

http://www.ncbi.nlm.nih.gov/pubmed/22821876
 
Back
Top Bottom